EGFR and non-small cell lung carcinoma: Therefore, mutation profiling of major driver genes such as EGFR, KRAS, BRAF, NRAS, ALK, and ROS1 has been recommended by the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) for patients with advanced NSCLC (3, 4).